Clinical momentum Syntara is advancing multiple Phase 2 studies in high-need blood cancer and fibrosis-related diseases, with a Phase 1c/2 program in myelodysplastic syndrome and interim data expected in 2024, presenting ongoing opportunities for strategic partnerships, CRO collaborations, and potential co-development deals.

Strategic collaborations Active partnerships include pan-LOX inhibitor programs with the University of Western Australia and Professor Fiona Wood, plus SSAO/MAOB inhibitor work with Parkinson’s UK, signaling avenues to expand licensing, collaboration revenue, and joint development initiatives beyond core assets.

Commercial footholds Existing respiratory products Bronchitol and Aridol generate royalties, creating a diversified revenue base that provides cash flow to support clinical programs and offers cross-sell messaging for investors and potential licensees seeking adjacent healthcare solutions.

Regulatory validation Lead candidate SNT-5505 has FDA Orphan Drug Designation and has cleared an IND for myelofibrosis, which can shorten development timelines and enhance talking points for investments, alliances, and strategic buyers looking for regulated pathways.

Financed growth With reported revenue in the low tens of millions and a scalable clinical portfolio, Syntara presents a compelling case for investor-aligned partnerships, CDMO engagement for scale-up manufacturing, and potential co-funding opportunities to accelerate late-stage trials.